Literature DB >> 20689561

Alzheimer disease: clinical use of cholinergic drugs in Alzheimer disease.

Julie Eve Desmarais, Serge Gauthier.   

Abstract

Drugs acting on the cholinergic system can improve or worsen cognitive abilities, and their effects are particularly pronounced in frail elderly individuals and patients with alzheimer disease. Guidelines are urgently needed on the judicious use of cholinergic drugs.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20689561     DOI： 10.1038/nrneurol.2010.105

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


  5 in total

1.  Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition.

Authors:  Stephen J Kogut; Diala El-Maouche; Susan M Abughosh
Journal:  Pharmacotherapy       Date:  2005-12       Impact factor: 4.705

2.  Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: a 2-year prospective, multicentre, cohort study.

Authors:  Virginie Gardette; Sandrine Andrieu; Maryse Lapeyre-Mestre; Nicola Coley; Christelle Cantet; Pierre-Jean Ousset; Alain Grand; Jean-Louis Monstastruc; Bruno Vellas
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

3.  Ten years of cholinesterase inhibitors.

Authors:  Joanne Rodda; Zuzana Walker
Journal:  Int J Geriatr Psychiatry       Date:  2009-05       Impact factor: 3.485

4.  A population-based study of cholinesterase inhibitor use for dementia.

Authors:  Nathan Herrmann; Sudeep S Gill; Chaim M Bell; Geoffrey M Anderson; Susan E Bronskill; Kenneth I Shulman; Hadas D Fischer; Kathy Sykora; Haijiang Steven Shi; Paula A Rochon
Journal:  J Am Geriatr Soc       Date:  2007-08-14       Impact factor: 5.562

Review 5.  Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology.

Authors:  Alistair Burns; John O'Brien; Sophie Auriacombe; Clive Ballard; Karl Broich; Roger Bullock; Howard Feldman; Gary Ford; Martin Knapp; Andrew McCaddon; Steve Iliffe; Claudia Jacova; Roy Jones; Sean Lennon; Ian McKeith; Jean-Marc Orgogozo; Nitin Purandare; Mervyn Richardson; Craig Ritchie; Alan Thomas; James Warner; Gordon Wilcock; David Wilkinson
Journal:  J Psychopharmacol       Date:  2006-11       Impact factor: 4.153
  5 in total
  2 in total

1.  Design and synthesis of new indole drug candidates to treat Alzheimer's disease and targeting neuro-inflammation using a multi-target-directed ligand (MTDL) strategy.

Authors:  Phoebe F Lamie; Maha M Abdel-Fattah; John N Philoppes
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

2.  Repetitive Transcranial Magnetic Stimulation Improves Brain-Derived Neurotrophic Factor and Cholinergic Signaling in the 3xTgAD Mouse Model of Alzheimer's Disease.

Authors:  M Windy McNerney; Alesha Heath; Sindhu K Narayanan; Jerome Yesavage
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.